Table 6.

Multivariable linear regression showing associations among host, treatment, and lifestyle factors among ALL survivors treated without CRT (n = 216)

	Sit and reach test (cm)			Ankle dorsiflexion ROM (°)			Modified total neuropathy score*			Sensory organization test (%)			Grip strength (kg)			Quadriceps strength 60°/s (Nm/kg)			Quadriceps strength 300°/s (Nm/kg)			Dorsiflexion strength 60°/s (Nm/kg)			Dorsiflexion strength 90°/s (Nm/kg)			Peak VO2 (mL/kg per min)
	β	SE	P	β	SE	P	β	SE	P	β	SE	P	β	SE	P	β	SE	P	β	SE	P	β	SE	P	β	SE	P	β	SE	P
Female sex	9.51	1.32	<.001	1.42	0.95	.14	0.20	0.34	.57	−0.25	1.14	.83	−20.04	1.00	<.001	−50.96	6.79	<.001	−19.68	3.83	<.001	−4.92	1.40	<.001	−2.45	1.10	.03	−3.91	0.80	<.001
Age (y)	−0.39	0.13	.003	0.04	0.09	.65	0.07	0.03	.10	−0.12	0.11	.27	−0.21	0.10	.03	−1.98	0.63	.002	−1.28	0.36	<.001	−0.19	0.14	.18	−0.16	0.11	.14	−0.21	0.08	.009
Asparaginase ≥120 000 IU/m2	−4.81	1.49	.001	−2.40	1.07	.03			NS			NS			NS			NS			NS			NS			NS			NS
Glucocorticoids ≥8000 mg/m2†			NS			NS			NS			NS	−2.18	1.03	.04			NS			NS			NS			NS			NS
IT methotrexate ≥225 mg2			NS			NS			NS	−4.11	1.93	.03			NS			NS			NS	−5.17	2.41	.03	−3.89	1.88	0.04			NS
IV methotrexate ≥16 000 mg/m2			NS			NS			NS			NS			NS			NS			NS	−2.87	1.53	.06	−1.84	1.20	0.12			NS
Vincristine ≥39 mg/m2			NS			NS	1.10	0.36	.003			NS			NS			NS			NS			NS			NS			NS
<30 min/day MVPA			NS			NS			NS			NS	−2.83	1.17	.02			NS			NS			NS			NS	−3.50	0.92	<.001
Current smoker			NS			NS	0.75	0.38	.05			NS			NS			NS			NS			NS			NS			NS

Variables with P > .10 in univariate analyses were not included in multiple-variable models (anthracyclines, epipodophyllotoxins, cytarabine, 6-mercaptopurine); variables with P < .10 in multivariable models were retained.

NS, nonsignificant; ROM, range of motion; SE, standard error; IT, intrathecal.

^*Higher is worse.

^†Prednisone equivalent dose.